15 Oct FDA perspective on the regulation of artificial intelligence in health care and biomedicine

By Haider J, Warraich, MD; Troy Tazbaz, BS; and Robert M. Califf, MD, JAMA

This article reviews the history of the US Food and Drug Administration’s (FDA) regulation of AI; presents potential uses of AI in medical product development, clinical research, and clinical care; and presents concepts that merit consideration as the regulatory system adapts to AI’s unique challenges. Read more …